182 related articles for article (PubMed ID: 24324964)
1. CYP19 genetic polymorphism haplotype AASA is associated with a poor prognosis in premenopausal women with lymph node-negative, hormone receptor-positive breast cancer.
Kuo SH; Yang SY; Lien HC; Lo C; Lin CH; Lu YS; Cheng AL; Chang KJ; Huang CS
Biomed Res Int; 2013; 2013():562197. PubMed ID: 24324964
[TBL] [Abstract][Full Text] [Related]
2. The CYP19 TTTA repeat polymorphism is related to the prognosis of premenopausal stage I-II and operable stage III breast cancers.
Huang CS; Kuo SH; Lien HC; Yang SY; You SL; Shen CY; Lin CH; Lu YS; Chang KJ
Oncologist; 2008 Jul; 13(7):751-60. PubMed ID: 18614591
[TBL] [Abstract][Full Text] [Related]
3. S4646 polymorphism in CYP19A1 gene is associated with the efficacy of hormone therapy in early breast cancer.
Shao X; Cai J; Zheng Y; Wang J; Feng J; Huang Y; Shi L; Chen Z; Guo Y; Wang X
Int J Clin Exp Pathol; 2015; 8(5):5309-17. PubMed ID: 26191232
[TBL] [Abstract][Full Text] [Related]
4. The CYP19 RS4646 polymorphism IS related to the prognosis of stage I-II and operable stage III breast cancer.
Shao X; Guo Y; Xu X; Zheng Y; Wang J; Chen Z; Huang J; Huang P; Cai J; Wang X
PLoS One; 2015; 10(3):e0121535. PubMed ID: 25793413
[TBL] [Abstract][Full Text] [Related]
5. Polymorphisms of ESR1, UGT1A1, HCN1, MAP3K1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer.
Kuo SH; Yang SY; You SL; Lien HC; Lin CH; Lin PH; Huang CS
Oncotarget; 2017 Mar; 8(13):20925-20938. PubMed ID: 28178648
[TBL] [Abstract][Full Text] [Related]
6. A CYP19 (aromatase) polymorphism is associated with increased premenopausal breast cancer risk.
Talbott KE; Gammon MD; Kibriya MG; Chen Y; Teitelbaum SL; Long CM; Gurvich I; Santella RM; Ahsan H
Breast Cancer Res Treat; 2008 Oct; 111(3):481-7. PubMed ID: 17975727
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of locally advanced breast cancer patients with ≥ 10 positive axillary lymph nodes.
Koca E; Kuzan TY; Dizdar O; Babacan T; Sahin I; Ararat E; Altundag K
Med Oncol; 2013; 30(3):615. PubMed ID: 23729267
[TBL] [Abstract][Full Text] [Related]
8. Distinct prevalence of the CYP19 Delta3(TTTA)(7) allele in premenopausal versus postmenopausal breast cancer patients, but not in control individuals.
Suspitsin EN; Grigoriev MY; Togo AV; Kuligina ES; Belogubova EV; Pozharisski KM; Chagunava OL; Sokolov EP; Theillet C; Berstein LM; Hanson KP; Imyanitov EN
Eur J Cancer; 2002 Sep; 38(14):1911-6. PubMed ID: 12204674
[TBL] [Abstract][Full Text] [Related]
9. CYP19 (aromatase) haplotypes and endometrial cancer risk.
Paynter RA; Hankinson SE; Colditz GA; Kraft P; Hunter DJ; De Vivo I
Int J Cancer; 2005 Aug; 116(2):267-74. PubMed ID: 15800924
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.
Yamashita H; Ogiya A; Shien T; Horimoto Y; Masuda N; Inao T; Osako T; Takahashi M; Endo Y; Hosoda M; Ishida N; Horii R; Yamazaki K; Miyoshi Y; Yasojima H; Tomioka N;
Breast Cancer; 2016 Nov; 23(6):830-843. PubMed ID: 26467036
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry.
Inwald EC; Koller M; Klinkhammer-Schalke M; Zeman F; Hofstädter F; Lindberg P; Gerstenhauer M; Schüler S; Treeck O; Ortmann O
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2229-40. PubMed ID: 26253629
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphisms and haplotype of hormone-related genes are associated with the risk of breast cancer in Chinese women.
Pan Z; Fu Z; Song Q; Cao W; Cheng W; Xu X
Genet Mol Res; 2016 May; 15(2):. PubMed ID: 27323034
[TBL] [Abstract][Full Text] [Related]
13. Hormone receptors and HER-2 status as surrogates for breast cancer molecular subtypes prognosticate for disease control in node negative Asian patients treated with breast conservation therapy.
Wong FY; Chin FK; Lee KA; Soong YL; Chua ET
Ann Acad Med Singap; 2011 Feb; 40(2):90-6. PubMed ID: 21468463
[TBL] [Abstract][Full Text] [Related]
14. BRCA1 breast cancer risk is modified by CYP19 polymorphisms in Ashkenazi Jews.
Raskin L; Lejbkowicz F; Barnett-Griness O; Dishon S; Almog R; Rennert G
Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1617-23. PubMed ID: 19366906
[TBL] [Abstract][Full Text] [Related]
15. Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients.
Fasching PA; Loehberg CR; Strissel PL; Lux MP; Bani MR; Schrauder M; Geiler S; Ringleff K; Oeser S; Weihbrecht S; Schulz-Wendtland R; Hartmann A; Beckmann MW; Strick R
Breast Cancer Res Treat; 2008 Nov; 112(1):89-98. PubMed ID: 18049890
[TBL] [Abstract][Full Text] [Related]
16. Association of genetic polymorphisms in CYP19 and CYP1A1 with the oestrogen receptor-positive breast cancer risk.
Miyoshi Y; Ando A; Hasegawa S; Ishitobi M; Yamamura J; Irahara N; Tanji Y; Taguchi T; Tamaki Y; Noguchi S
Eur J Cancer; 2003 Nov; 39(17):2531-7. PubMed ID: 14602139
[TBL] [Abstract][Full Text] [Related]
17. Effect of CYP19 rs6493497 and rs7176005 haplotype status on in vivo aromatase transcription, plasma and tissue estrogen levels in postmenopausal women.
Straume AH; Knappskog S; Lønning PE
J Steroid Biochem Mol Biol; 2012 Jan; 128(1-2):69-75. PubMed ID: 21939764
[TBL] [Abstract][Full Text] [Related]
18. The prognostic value of IL10 and TNF alpha functional polymorphisms in premenopausal early-stage breast cancer patients.
Korobeinikova E; Myrzaliyeva D; Ugenskiene R; Raulinaityte D; Gedminaite J; Smigelskas K; Juozaityte E
BMC Genet; 2015 Jun; 16():70. PubMed ID: 26112140
[TBL] [Abstract][Full Text] [Related]
19. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.
Regan MM; Viale G; Mastropasqua MG; Maiorano E; Golouh R; Carbone A; Brown B; Suurküla M; Langman G; Mazzucchelli L; Braye S; Grigolato P; Gelber RD; Castiglione-Gertsch M; Price KN; Coates AS; Goldhirsch A; Gusterson B;
J Natl Cancer Inst; 2006 Nov; 98(21):1571-81. PubMed ID: 17077359
[TBL] [Abstract][Full Text] [Related]
20. Polymorphisms of estrogen-metabolizing genes and breast cancer risk: a multigenic study.
Han DF; Zhou X; Hu MB; Xie W; Mao ZF; Chen DE; Liu F; Zheng F
Chin Med J (Engl); 2005 Sep; 118(18):1507-16. PubMed ID: 16232327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
